# Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 7.9 | 76.2 | (27.8-165.9) |  | Male | 16 | 5.3 | 301.0 | (171.9-488.8) |
| Female | 3 | 2.6 | nc | (nc-nc) |  | Female | 3 | 4.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 3 | 1.2 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 5 | 4.6 | 107.6 | (34.7-251.2) |
| Female | 44 | 32.1 | 137.2 | (99.7-184.2) |  | Female | 4 | 3.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 4.1 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 11 | 9.0 | 122.5 | (61.0-219.1) |  |  |  |  |  |  |
| Female | 10 | 8.0 | 124.4 | (59.6-228.8) |  | Female | 4 | 2.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 2.3 | nc | (nc-nc) |  | Male | 2 | 2.8 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 2.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 40 | 32.5 | 123.0 | (87.8-167.5) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 4.7 | nc | (nc-nc) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 2 | 2.4 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 3.1 | nc | (nc-nc) |  | Male | 3 | 2.1 | nc | (nc-nc) |
| Female | 2 | 2.1 | nc | (nc-nc) |  | Female | 7 | 5.8 | 121.1 | (48.5-249.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 3.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 8 | 7.5 | 106.2 | (45.7-209.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 9 | 14.9 | 60.5 | (27.6-114.9) |  | Male | 113 | 112.3 | 100.7 | (83.0-121.0) |
| Female | 11 | 14.2 | 77.3 | (38.5-138.3) |  | Female | 113 | 103.7 | 108.9 | (89.8-131.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

214

# Newburyport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 22 | 20.7 | 106.3 | (66.6-160.9) |  | Male | 24 | 13.5 | 178.2 | (114.2-265.2) |
| Female | 8 | 8.5 | 93.9 | (40.4-185.0) |  | Female | 16 | 11.6 | 137.7 | (78.6-223.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 3.8 | nc | (nc-nc) |  | Male | 1 | 4.0 | nc | (nc-nc) |
| Female | 2 | 3.5 | nc | (nc-nc) |  | Female | 6 | 3.6 | 165.0 | (60.2-359.1) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 14 | 11.8 | 118.7 | (64.9-199.2) |
| Female | 91 | 91.5 | 99.4 | (80.1-122.1) |  | Female | 8 | 11.3 | 71.0 | (30.6-139.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 17 | 9.8 | 173.7 | (101.1-278.1) |
| Female | 0 | 3.0 | nc | (nc-nc) |  | Female | 3 | 4.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 25 | 23.0 | 108.9 | (70.5-160.8) |  |  |  |  |  |  |
| Female | 26 | 26.0 | 99.9 | (65.3-146.5) |  | Female | 9 | 8.4 | 107.6 | (49.1-204.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 5.7 | 105.1 | (38.4-228.8) |  | Male | 7 | 7.1 | 98.0 | (39.3-202.0) |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 8 | 8.4 | 95.7 | (41.2-188.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 85 | 77.7 | 109.5 | (87.4-135.4) |
| Female | 2 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 11 | 11.5 | 96.0 | (47.9-171.8) |  | Male | 6 | 4.9 | 123.2 | (45.0-268.1) |
| Female | 4 | 7.3 | nc | (nc-nc) |  | Female | 6 | 3.3 | 183.6 | (67.1-399.7) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 3.2 | nc | (nc-nc) |  | Male | 2 | 2.2 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 8.1 | 99.3 | (42.8-195.7) |  | Male | 9 | 5.1 | 176.6 | (80.6-335.2) |
| Female | 5 | 6.6 | 75.6 | (24.4-176.5) |  | Female | 18 | 15.8 | 113.9 | (67.5-180.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 7.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 2.6 | nc | (nc-nc) |  | Female | 16 | 21.2 | 75.3 | (43.0-122.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 30 | 38.1 | 78.8 | (53.2-112.5) |  | Male | 293 | 280.0 | 104.6 | (93.0-117.3) |
| Female | 43 | 43.6 | 98.7 | (71.4-132.9) |  | Female | 306 | 309.8 | 98.8 | (88.0-110.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

215

# Newton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 93 | 98.2 | 94.7 | (76.4-116.0) |  | Male | 69 | 61.3 | 112.5 | (87.5-142.4) |
| Female | 42 | 36.8 | 114.1 | (82.2-154.3) |  | Female | 67 | 50.3 | 133.3 | (103.3-169.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 21 | 17.4 | 120.9 | (74.8-184.9) |  | Male | 25 | 18.2 | 137.4 | (88.9-202.8) |
| Female | 17 | 15.7 | 108.1 | (62.9-173.1) |  | Female | 18 | 15.5 | 116.1 | (68.7-183.4) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 3.0 | nc | (nc-nc) |  | Male | 56 | 54.5 | 102.7 | (77.6-133.4) |
| Female | 457 | 381.0 | 119.9 | (109.2-131.5) |  | Female | 53 | 48.3 | 109.7 | (82.1-143.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 40 | 42.6 | 93.9 | (67.1-127.9) |
| Female | 12 | 12.9 | 92.8 | (47.9-162.1) |  | Female | 26 | 20.0 | 130.0 | (84.9-190.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 90 | 105.8 | 85.0 | (68.4-104.5) |  |  |  |  |  |  |
| Female | 91 | 112.1 | 81.1 | (65.3-99.6) |  | Female | 39 | 35.3 | 110.4 | (78.5-151.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 9 | 25.5 | 35.2 | (16.1-66.9) |  | Male | 34 | 33.0 | 103.2 | (71.4-144.2) |
| Female | 7 | 7.0 | 99.8 | (40.0-205.7) |  | Female | 48 | 36.2 | 132.5 | (97.7-175.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 7.1 | nc | (nc-nc) |  | Male | 362 | 337.6 | 107.2 | (96.5-118.9) |
| Female | 4 | 6.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 51 | 50.3 | 101.5 | (75.6-133.4) |  | Male | 18 | 22.5 | 79.9 | (47.3-126.2) |
| Female | 22 | 30.7 | 71.7 | (44.9-108.6) |  | Female | 15 | 14.2 | 105.4 | (59.0-173.9) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 9 | 14.0 | 64.3 | (29.4-122.1) |  | Male | 13 | 11.1 | 117.2 | (62.3-200.4) |
| Female | 1 | 4.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 46 | 38.3 | 120.2 | (88.0-160.4) |  | Male | 34 | 22.2 | 153.1 | (106.0-214.0) |
| Female | 25 | 29.2 | 85.7 | (55.5-126.6) |  | Female | 82 | 68.8 | 119.3 | (94.8-148.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 28 | 31.9 | 87.9 | (58.4-127.0) |  |  |  |  |  |  |
| Female | 11 | 10.9 | 100.8 | (50.3-180.5) |  | Female | 87 | 87.4 | 99.6 | (79.8-122.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 127 | 174.6 | 72.8 | (60.6-86.6) |  | Male | 1203 | 1268.4 | 94.8 | (89.6-100.4) |
| Female | 148 | 185.0 | 80.0 | (67.6-94.0) |  | Female | 1400 | 1316.6 | 106.3 | (100.8-112.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

216

# Norfolk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 10.6 | 75.6 | (32.6-149.0) |  | Male | 12 | 8.3 | 145.2 | (75.0-253.7) |
| Female | 3 | 2.6 | nc | (nc-nc) |  | Female | 6 | 4.4 | 135.5 | (49.5-294.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.6 | nc | (nc-nc) |  | Male | 3 | 2.3 | nc | (nc-nc) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 7 | 7.2 | 96.9 | (38.8-199.7) |
| Female | 53 | 35.7 | 148.3 | (111.1-194.0) |  | Female | 0 | 3.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 6.7 | nc | (nc-nc) |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 12 | 13.5 | 88.6 | (45.7-154.8) |  |  |  |  |  |  |
| Female | 7 | 8.2 | 85.4 | (34.2-176.0) |  | Female | 1 | 3.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 3.4 | nc | (nc-nc) |  | Male | 2 | 4.0 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 3 | 2.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 49 | 47.6 | 103.0 | (76.2-136.2) |
| Female | 1 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 7.5 | 79.6 | (29.1-173.3) |  | Male | 6 | 2.8 | 217.0 | (79.2-472.4) |
| Female | 2 | 2.6 | nc | (nc-nc) |  | Female | 2 | 1.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 1.9 | nc | (nc-nc) |  | Male | 3 | 2.2 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 4.7 | nc | (nc-nc) |  | Male | 2 | 4.0 | nc | (nc-nc) |
| Female | 3 | 2.3 | nc | (nc-nc) |  | Female | 6 | 7.2 | 83.8 | (30.6-182.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 4.6 | 151.5 | (60.7-312.2) |  |  |  |  |  |  |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 7 | 8.2 | 85.7 | (34.3-176.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 20 | 20.4 | 98.1 | (59.9-151.5) |  | Male | 157 | 167.3 | 93.8 | (79.7-109.7) |
| Female | 10 | 14.2 | 70.3 | (33.6-129.3) |  | Female | 113 | 111.6 | 101.3 | (83.5-121.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

217

# North Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 19 | 15.6 | 121.9 | (73.3-190.3) |  | Male | 6 | 9.8 | 61.5 | (22.5-133.9) |
| Female | 13 | 6.4 | 203.1 | (108.0-347.3) |  | Female | 5 | 8.2 | 60.9 | (19.6-142.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 2.7 | 182.1 | (58.7-424.9) |  | Male | 5 | 2.9 | 173.4 | (55.9-404.7) |
| Female | 1 | 2.6 | nc | (nc-nc) |  | Female | 2 | 2.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 8 | 8.7 | 92.4 | (39.8-182.0) |
| Female | 52 | 60.8 | 85.5 | (63.8-112.1) |  | Female | 6 | 8.1 | 73.7 | (26.9-160.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 6.7 | 120.2 | (51.7-236.8) |
| Female | 1 | 2.0 | nc | (nc-nc) |  | Female | 2 | 3.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 26 | 16.7 | 155.4 | (101.5-227.7) |  |  |  |  |  |  |
| Female | 24 | 19.3 | 124.4 | (79.7-185.1) |  | Female | 6 | 5.7 | 104.7 | (38.2-227.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 10 | 4.0 | 249.0 | (119.2-458.0) |  | Male | 2 | 5.2 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 11 | 6.3 | 174.9 | (87.2-313.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 52 | 52.7 | 98.6 | (73.6-129.3) |
| Female | 1 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 14 | 7.9 | 176.8 | (96.6-296.7) |  | Male | 5 | 3.6 | 140.3 | (45.2-327.4) |
| Female | 2 | 5.1 | nc | (nc-nc) |  | Female | 3 | 2.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.2 | nc | (nc-nc) |  | Male | 2 | 2.0 | nc | (nc-nc) |
| Female | 4 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 6.1 | 82.6 | (26.6-192.8) |  | Male | 3 | 3.5 | nc | (nc-nc) |
| Female | 7 | 5.0 | 141.4 | (56.6-291.3) |  | Female | 11 | 10.7 | 103.1 | (51.4-184.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 11 | 5.0 | 219.1 | (109.2-392.1) |  |  |  |  |  |  |
| Female | 3 | 1.8 | nc | (nc-nc) |  | Female | 11 | 13.8 | 80.0 | (39.9-143.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 41 | 27.8 | 147.4 | (105.7-199.9) |  | Male | 240 | 200.5 | 119.7 | (105.0-135.8) |
| Female | 42 | 31.9 | 131.8 | (95.0-178.2) |  | Female | 220 | 217.6 | 101.1 | (88.2-115.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

218

# North Andover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 37 | 27.6 | 134.1 | (94.4-184.8) |  | Male | 23 | 18.2 | 126.4 | (80.1-189.7) |
| Female | 14 | 11.3 | 123.6 | (67.5-207.3) |  | Female | 15 | 15.8 | 94.9 | (53.1-156.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 5.5 | 109.5 | (40.0-238.4) |  | Male | 4 | 5.3 | nc | (nc-nc) |
| Female | 5 | 5.0 | 100.9 | (32.5-235.4) |  | Female | 5 | 4.8 | 105.0 | (33.8-245.1) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 4 | 0.9 | nc | (nc-nc) |  | Male | 13 | 16.2 | 80.2 | (42.7-137.1) |
| Female | 117 | 119.9 | 97.6 | (80.7-117.0) |  | Female | 17 | 15.0 | 113.7 | (66.2-182.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 12 | 13.1 | 91.5 | (47.2-159.8) |
| Female | 4 | 4.3 | nc | (nc-nc) |  | Female | 4 | 6.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 27 | 31.2 | 86.4 | (56.9-125.8) |  |  |  |  |  |  |
| Female | 40 | 35.4 | 112.9 | (80.6-153.7) |  | Female | 11 | 11.0 | 100.4 | (50.1-179.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 7.4 | 94.2 | (37.7-194.1) |  | Male | 13 | 9.5 | 137.3 | (73.1-234.9) |
| Female | 1 | 2.1 | nc | (nc-nc) |  | Female | 13 | 11.2 | 115.9 | (61.6-198.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 5 | 2.3 | 217.6 | (70.1-507.8) |  | Male | 115 | 98.9 | 116.3 | (96.0-139.6) |
| Female | 4 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 19 | 15.3 | 124.0 | (74.6-193.6) |  | Male | 6 | 6.5 | 91.8 | (33.5-199.7) |
| Female | 5 | 9.5 | 52.7 | (17.0-122.9) |  | Female | 5 | 4.5 | 110.7 | (35.7-258.3) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 4.1 | nc | (nc-nc) |  | Male | 5 | 3.8 | 132.3 | (42.6-308.8) |
| Female | 0 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 12 | 11.3 | 105.9 | (54.6-185.0) |  | Male | 9 | 7.2 | 124.9 | (57.0-237.1) |
| Female | 9 | 9.2 | 97.5 | (44.5-185.1) |  | Female | 31 | 22.4 | 138.5 | (94.1-196.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 9.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 3.3 | nc | (nc-nc) |  | Female | 17 | 26.5 | 64.2 | (37.4-102.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 35 | 49.5 | 70.7 | (49.3-98.4) |  | Male | 391 | 372.1 | 105.1 | (94.9-116.0) |
| Female | 59 | 55.6 | 106.2 | (80.8-137.0) |  | Female | 412 | 410.2 | 100.4 | (91.0-110.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

219

# North Attleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 18 | 24.3 | 74.2 | (44.0-117.3) |  | Male | 19 | 17.2 | 110.5 | (66.5-172.6) |
| Female | 6 | 8.9 | 67.6 | (24.7-147.1) |  | Female | 20 | 14.5 | 137.6 | (84.0-212.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 5.4 | 129.8 | (52.0-267.5) |  | Male | 1 | 4.9 | nc | (nc-nc) |
| Female | 6 | 4.5 | 132.7 | (48.4-288.8) |  | Female | 5 | 3.9 | 128.9 | (41.5-300.8) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 18 | 15.2 | 118.5 | (70.2-187.3) |
| Female | 106 | 110.2 | 96.2 | (78.7-116.3) |  | Female | 12 | 12.6 | 95.1 | (49.1-166.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 12 | 12.9 | 93.2 | (48.1-162.8) |
| Female | 2 | 4.3 | nc | (nc-nc) |  | Female | 7 | 5.4 | 130.3 | (52.2-268.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 38 | 28.7 | 132.2 | (93.6-181.5) |  |  |  |  |  |  |
| Female | 27 | 28.1 | 96.2 | (63.4-140.0) |  | Female | 7 | 9.8 | 71.1 | (28.5-146.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 7.0 | 100.6 | (40.3-207.3) |  | Male | 6 | 8.6 | 69.9 | (25.5-152.2) |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 10 | 8.6 | 116.0 | (55.5-213.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 2.4 | nc | (nc-nc) |  | Male | 103 | 95.0 | 108.4 | (88.5-131.5) |
| Female | 1 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 15.0 | 66.8 | (32.0-122.9) |  | Male | 4 | 6.0 | nc | (nc-nc) |
| Female | 7 | 8.4 | 83.4 | (33.4-171.8) |  | Female | 1 | 3.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 9 | 3.9 | 230.9 | (105.4-438.4) |  | Male | 4 | 4.3 | nc | (nc-nc) |
| Female | 0 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 10.4 | 76.7 | (33.0-151.2) |  | Male | 4 | 7.5 | nc | (nc-nc) |
| Female | 5 | 7.7 | 64.7 | (20.8-150.9) |  | Female | 30 | 23.0 | 130.3 | (87.9-186.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 9 | 9.2 | 98.0 | (44.7-186.1) |  |  |  |  |  |  |
| Female | 1 | 2.8 | nc | (nc-nc) |  | Female | 25 | 24.6 | 101.7 | (65.8-150.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 47 | 44.9 | 104.7 | (76.9-139.2) |  | Male | 356 | 349.1 | 102.0 | (91.6-113.1) |
| Female | 44 | 46.9 | 93.8 | (68.2-126.0) |  | Female | 342 | 360.0 | 95.0 | (85.2-105.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

220

# North Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 5.1 | nc | (nc-nc) |  | Male | 5 | 3.4 | 148.6 | (47.9-346.7) |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 2 | 2.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.0 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 3 | 3.0 | nc | (nc-nc) |
| Female | 20 | 19.8 | 101.1 | (61.7-156.2) |  | Female | 1 | 2.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 2.5 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 2 | 1.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 5.7 | 104.6 | (38.2-227.6) |  |  |  |  |  |  |
| Female | 3 | 5.5 | nc | (nc-nc) |  | Female | 4 | 1.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 1.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 21 | 19.1 | 110.0 | (68.0-168.1) |
| Female | 2 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 2.9 | nc | (nc-nc) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 2.0 | nc | (nc-nc) |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 2 | 3.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 6 | 4.5 | 134.2 | (49.0-292.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 7 | 9.2 | 75.8 | (30.3-156.1) |  | Male | 65 | 69.5 | 93.5 | (72.1-119.1) |
| Female | 6 | 9.2 | 64.9 | (23.7-141.3) |  | Female | 53 | 66.8 | 79.4 | (59.5-103.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

221

# North Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 15.2 | 72.4 | (36.1-129.6) |  | Male | 17 | 10.3 | 164.8 | (95.9-263.8) |
| Female | 9 | 5.2 | 173.6 | (79.2-329.6) |  | Female | 14 | 8.0 | 175.2 | (95.7-294.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 3.1 | 195.5 | (71.4-425.4) |  | Male | 3 | 3.0 | nc | (nc-nc) |
| Female | 2 | 2.5 | nc | (nc-nc) |  | Female | 0 | 2.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 11 | 9.1 | 121.3 | (60.5-217.0) |
| Female | 70 | 62.8 | 111.5 | (86.9-140.8) |  | Female | 8 | 7.2 | 110.6 | (47.6-217.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 7.6 | nc | (nc-nc) |
| Female | 2 | 2.2 | nc | (nc-nc) |  | Female | 1 | 3.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 20 | 17.5 | 114.5 | (69.9-176.9) |  |  |  |  |  |  |
| Female | 16 | 16.1 | 99.2 | (56.7-161.2) |  | Female | 3 | 5.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 4.3 | 140.5 | (51.3-305.9) |  | Male | 2 | 5.3 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 4 | 5.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 1.3 | nc | (nc-nc) |  | Male | 55 | 58.1 | 94.7 | (71.3-123.2) |
| Female | 2 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 8.9 | 90.1 | (38.8-177.5) |  | Male | 2 | 3.7 | nc | (nc-nc) |
| Female | 2 | 4.8 | nc | (nc-nc) |  | Female | 0 | 2.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 2.4 | nc | (nc-nc) |  | Male | 1 | 2.0 | nc | (nc-nc) |
| Female | 2 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 6.2 | 145.3 | (66.3-275.8) |  | Male | 2 | 4.2 | nc | (nc-nc) |
| Female | 6 | 4.3 | 139.3 | (50.9-303.3) |  | Female | 16 | 12.1 | 132.1 | (75.5-214.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 5.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 15 | 14.2 | 105.9 | (59.3-174.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 20 | 28.1 | 71.1 | (43.4-109.9) |  | Male | 204 | 211.9 | 96.3 | (83.5-110.4) |
| Female | 16 | 27.8 | 57.6 | (32.9-93.6) |  | Female | 203 | 205.1 | 99.0 | (85.8-113.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

222

# Northampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 30 | 30.0 | 100.1 | (67.5-142.9) |  | Male | 10 | 19.4 | 51.5 | (24.6-94.7) |
| Female | 9 | 11.6 | 77.6 | (35.4-147.3) |  | Female | 12 | 17.2 | 69.8 | (36.0-121.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 5.5 | 109.2 | (39.9-237.7) |  | Male | 0 | 5.7 | nc | (nc-nc) |
| Female | 7 | 5.2 | 133.8 | (53.6-275.6) |  | Female | 6 | 4.9 | 121.4 | (44.3-264.2) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 16 | 17.1 | 93.4 | (53.4-151.7) |
| Female | 142 | 125.5 | 113.2 | (95.3-133.4) |  | Female | 15 | 15.6 | 96.0 | (53.7-158.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 14.0 | 71.4 | (34.2-131.3) |
| Female | 3 | 4.5 | nc | (nc-nc) |  | Female | 9 | 6.5 | 137.6 | (62.8-261.2) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 33 | 33.1 | 99.6 | (68.5-139.8) |  |  |  |  |  |  |
| Female | 33 | 35.7 | 92.3 | (63.5-129.7) |  | Female | 17 | 11.8 | 144.5 | (84.1-231.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 9 | 8.2 | 110.4 | (50.4-209.5) |  | Male | 9 | 10.3 | 87.5 | (39.9-166.2) |
| Female | 3 | 2.2 | nc | (nc-nc) |  | Female | 15 | 11.4 | 131.5 | (73.6-216.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 2.3 | nc | (nc-nc) |  | Male | 82 | 110.2 | 74.4 | (59.2-92.4) |
| Female | 2 | 2.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 12 | 16.2 | 73.9 | (38.2-129.2) |  | Male | 3 | 7.0 | nc | (nc-nc) |
| Female | 12 | 9.9 | 120.9 | (62.4-211.3) |  | Female | 5 | 4.5 | 110.2 | (35.5-257.2) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 4.5 | nc | (nc-nc) |  | Male | 4 | 3.9 | nc | (nc-nc) |
| Female | 1 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 11.7 | 76.6 | (35.0-145.5) |  | Male | 5 | 7.5 | 67.0 | (21.6-156.4) |
| Female | 8 | 9.4 | 85.4 | (36.8-168.2) |  | Female | 11 | 24.8 | 44.4 | (22.1-79.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 11 | 10.4 | 105.7 | (52.7-189.2) |  |  |  |  |  |  |
| Female | 1 | 3.5 | nc | (nc-nc) |  | Female | 31 | 29.0 | 106.8 | (72.5-151.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 40 | 54.1 | 73.9 | (52.8-100.7) |  | Male | 317 | 402.6 | 78.7 | (70.3-87.9) |
| Female | 53 | 58.5 | 90.5 | (67.8-118.4) |  | Female | 425 | 430.5 | 98.7 | (89.5-108.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

223

# Northborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 19 | 14.2 | 133.5 | (80.3-208.4) |  | Male | 6 | 9.7 | 62.2 | (22.7-135.3) |
| Female | 8 | 5.4 | 147.9 | (63.7-291.4) |  | Female | 7 | 7.9 | 89.1 | (35.7-183.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 2.9 | nc | (nc-nc) |  | Male | 4 | 2.8 | nc | (nc-nc) |
| Female | 1 | 2.4 | nc | (nc-nc) |  | Female | 2 | 2.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 6 | 8.5 | 70.4 | (25.7-153.2) |
| Female | 59 | 61.9 | 95.4 | (72.6-123.0) |  | Female | 4 | 7.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 7.2 | nc | (nc-nc) |
| Female | 0 | 2.2 | nc | (nc-nc) |  | Female | 5 | 3.1 | 161.7 | (52.1-377.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 16.4 | 61.0 | (29.2-112.2) |  |  |  |  |  |  |
| Female | 22 | 16.8 | 131.0 | (82.0-198.3) |  | Female | 4 | 5.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 4.0 | 125.2 | (40.4-292.3) |  | Male | 9 | 5.0 | 181.7 | (82.9-345.0) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 5 | 5.3 | 95.0 | (30.6-221.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 56 | 53.9 | 103.8 | (78.4-134.8) |
| Female | 2 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 8.3 | nc | (nc-nc) |  | Male | 4 | 3.4 | nc | (nc-nc) |
| Female | 3 | 4.8 | nc | (nc-nc) |  | Female | 2 | 2.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 2.2 | nc | (nc-nc) |  | Male | 0 | 1.9 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 11 | 5.8 | 188.5 | (93.9-337.2) |  | Male | 2 | 3.9 | nc | (nc-nc) |
| Female | 4 | 4.4 | nc | (nc-nc) |  | Female | 8 | 11.4 | 69.9 | (30.1-137.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 5.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 17 | 13.8 | 122.9 | (71.5-196.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 17 | 26.2 | 64.8 | (37.7-103.7) |  | Male | 175 | 198.1 | 88.4 | (75.8-102.5) |
| Female | 18 | 28.2 | 63.9 | (37.9-101.0) |  | Female | 186 | 205.3 | 90.6 | (78.1-104.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

224

# Northbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 19 | 15.3 | 123.9 | (74.6-193.5) |  | Male | 5 | 10.1 | 49.5 | (16.0-115.5) |
| Female | 8 | 6.2 | 129.8 | (55.9-255.8) |  | Female | 6 | 8.7 | 69.3 | (25.3-150.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 3.0 | nc | (nc-nc) |  | Male | 6 | 2.9 | 205.2 | (74.9-446.7) |
| Female | 1 | 2.7 | nc | (nc-nc) |  | Female | 4 | 2.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 6 | 9.0 | 66.6 | (24.3-145.0) |
| Female | 56 | 64.9 | 86.3 | (65.2-112.1) |  | Female | 7 | 8.1 | 86.0 | (34.5-177.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 7.2 | 139.4 | (66.8-256.5) |
| Female | 2 | 2.3 | nc | (nc-nc) |  | Female | 5 | 3.4 | 148.9 | (48.0-347.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 19 | 17.4 | 109.4 | (65.8-170.8) |  |  |  |  |  |  |
| Female | 31 | 19.2 | 161.4 | (109.7-229.1) |  | Female | 6 | 5.9 | 101.0 | (36.9-219.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 4.1 | 148.0 | (54.0-322.1) |  | Male | 2 | 5.2 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 10 | 6.1 | 163.9 | (78.5-301.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 58 | 53.2 | 109.0 | (82.7-140.9) |
| Female | 0 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 18 | 8.4 | 213.8 | (126.7-337.9) |  | Male | 1 | 3.6 | nc | (nc-nc) |
| Female | 3 | 5.2 | nc | (nc-nc) |  | Female | 2 | 2.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.2 | nc | (nc-nc) |  | Male | 2 | 2.2 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 6.3 | 142.5 | (65.0-270.6) |  | Male | 3 | 4.0 | nc | (nc-nc) |
| Female | 3 | 5.0 | nc | (nc-nc) |  | Female | 13 | 12.4 | 105.2 | (56.0-180.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 5.2 | 115.1 | (42.0-250.5) |  |  |  |  |  |  |
| Female | 3 | 1.8 | nc | (nc-nc) |  | Female | 16 | 14.3 | 111.6 | (63.7-181.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 29 | 27.2 | 106.6 | (71.4-153.1) |  | Male | 225 | 204.6 | 110.0 | (96.1-125.3) |
| Female | 30 | 30.4 | 98.7 | (66.6-140.9) |  | Female | 222 | 223.1 | 99.5 | (86.8-113.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

225

# Northfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 3.9 | nc | (nc-nc) |  | Male | 2 | 2.5 | nc | (nc-nc) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 3 | 1.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 2.2 | nc | (nc-nc) |
| Female | 13 | 14.0 | 92.6 | (49.3-158.4) |  | Female | 0 | 1.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 4.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 3.8 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 10 | 14.4 | 69.5 | (33.3-127.8) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 2.1 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 2 | 1.0 | nc | (nc-nc) |  | Female | 2 | 2.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 4 | 3.3 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 7.1 | nc | (nc-nc) |  | Male | 38 | 52.0 | 73.0 | (51.7-100.2) |
| Female | 4 | 6.5 | nc | (nc-nc) |  | Female | 40 | 46.8 | 85.4 | (61.0-116.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

226

# Norton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 15.8 | 69.6 | (34.7-124.5) |  | Male | 13 | 11.2 | 116.3 | (61.8-198.8) |
| Female | 8 | 5.8 | 137.8 | (59.3-271.5) |  | Female | 13 | 9.4 | 137.8 | (73.3-235.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 3.5 | 143.3 | (46.2-334.3) |  | Male | 4 | 3.2 | nc | (nc-nc) |
| Female | 5 | 3.0 | 168.4 | (54.3-393.1) |  | Female | 2 | 2.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 7 | 9.9 | 70.7 | (28.3-145.6) |
| Female | 63 | 72.0 | 87.5 | (67.2-112.0) |  | Female | 12 | 8.3 | 144.8 | (74.7-252.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 9 | 8.5 | 106.3 | (48.5-201.7) |
| Female | 2 | 2.7 | nc | (nc-nc) |  | Female | 4 | 3.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 26 | 18.7 | 138.9 | (90.7-203.5) |  |  |  |  |  |  |
| Female | 29 | 18.1 | 160.2 | (107.3-230.1) |  | Female | 7 | 6.5 | 107.8 | (43.2-222.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 4.6 | 130.7 | (47.7-284.4) |  | Male | 9 | 5.6 | 159.9 | (73.0-303.6) |
| Female | 2 | 1.1 | nc | (nc-nc) |  | Female | 8 | 5.6 | 142.2 | (61.2-280.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.6 | nc | (nc-nc) |  | Male | 65 | 63.4 | 102.5 | (79.1-130.7) |
| Female | 0 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 11 | 9.8 | 112.4 | (56.0-201.1) |  | Male | 4 | 3.9 | nc | (nc-nc) |
| Female | 7 | 5.5 | 127.9 | (51.2-263.5) |  | Female | 2 | 2.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 2.6 | nc | (nc-nc) |  | Male | 5 | 2.8 | 180.6 | (58.2-421.5) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 6.8 | 103.3 | (41.4-212.9) |  | Male | 8 | 4.9 | 164.1 | (70.7-323.4) |
| Female | 6 | 5.0 | 119.9 | (43.8-260.9) |  | Female | 15 | 14.8 | 101.5 | (56.8-167.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 12 | 6.0 | 198.8 | (102.6-347.3) |  |  |  |  |  |  |
| Female | 0 | 1.8 | nc | (nc-nc) |  | Female | 23 | 16.3 | 141.1 | (89.4-211.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 28 | 29.5 | 95.0 | (63.1-137.2) |  | Male | 252 | 229.5 | 109.8 | (96.7-124.2) |
| Female | 30 | 31.1 | 96.6 | (65.2-137.9) |  | Female | 252 | 235.2 | 107.1 | (94.3-121.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

227

# Norwell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 10 | 12.3 | 81.3 | (38.9-149.5) |  | Male | 5 | 7.9 | 63.1 | (20.3-147.3) |
| Female | 1 | 4.6 | nc | (nc-nc) |  | Female | 14 | 6.2 | 226.0 | (123.4-379.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 2.3 | nc | (nc-nc) |  | Male | 2 | 2.4 | nc | (nc-nc) |
| Female | 2 | 2.0 | nc | (nc-nc) |  | Female | 4 | 2.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 4 | 7.0 | nc | (nc-nc) |
| Female | 43 | 49.3 | 87.2 | (63.1-117.4) |  | Female | 7 | 6.1 | 115.0 | (46.1-237.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 5.8 | nc | (nc-nc) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 7 | 2.5 | 276.6 | (110.8-570.0) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 11 | 13.6 | 80.7 | (40.2-144.4) |  |  |  |  |  |  |
| Female | 9 | 14.1 | 63.8 | (29.1-121.1) |  | Female | 8 | 4.5 | 179.0 | (77.1-352.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 3.4 | nc | (nc-nc) |  | Male | 4 | 4.3 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 7 | 4.5 | 154.4 | (61.9-318.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 45 | 45.9 | 98.1 | (71.6-131.3) |
| Female | 3 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 6.7 | nc | (nc-nc) |  | Male | 1 | 2.9 | nc | (nc-nc) |
| Female | 4 | 3.9 | nc | (nc-nc) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 4.8 | 123.9 | (45.2-269.6) |  | Male | 2 | 3.0 | nc | (nc-nc) |
| Female | 4 | 3.7 | nc | (nc-nc) |  | Female | 6 | 8.4 | 71.4 | (26.1-155.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 4.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 15 | 11.2 | 134.1 | (75.0-221.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 14 | 22.5 | 62.2 | (34.0-104.4) |  | Male | 132 | 165.6 | 79.7 | (66.7-94.5) |
| Female | 15 | 23.6 | 63.6 | (35.6-104.9) |  | Female | 168 | 167.0 | 100.6 | (85.9-117.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

228

# Norwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 21 | 34.6 | 60.6 | (37.5-92.7) |  | Male | 31 | 21.5 | 144.1 | (97.9-204.5) |
| Female | 11 | 13.9 | 79.0 | (39.4-141.3) |  | Female | 23 | 18.0 | 128.0 | (81.1-192.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 10 | 6.0 | 166.5 | (79.7-306.2) |  | Male | 10 | 6.3 | 157.7 | (75.5-290.1) |
| Female | 8 | 5.5 | 145.1 | (62.5-286.0) |  | Female | 7 | 5.8 | 121.5 | (48.7-250.3) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.1 | nc | (nc-nc) |  | Male | 24 | 19.1 | 125.9 | (80.7-187.4) |
| Female | 147 | 134.1 | 109.6 | (92.6-128.9) |  | Female | 16 | 17.7 | 90.3 | (51.6-146.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 15 | 14.3 | 104.6 | (58.5-172.5) |
| Female | 5 | 4.5 | 110.7 | (35.7-258.3) |  | Female | 4 | 7.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 51 | 37.0 | 137.9 | (102.7-181.4) |  |  |  |  |  |  |
| Female | 53 | 42.2 | 125.5 | (94.0-164.2) |  | Female | 15 | 12.5 | 120.3 | (67.3-198.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 10 | 8.7 | 114.7 | (54.9-211.0) |  | Male | 16 | 11.4 | 139.9 | (79.9-227.2) |
| Female | 4 | 2.6 | nc | (nc-nc) |  | Female | 18 | 13.7 | 131.3 | (77.8-207.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 5 | 2.5 | 198.3 | (63.9-462.8) |  | Male | 88 | 112.4 | 78.3 | (62.8-96.5) |
| Female | 2 | 2.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 18 | 17.2 | 104.5 | (61.9-165.1) |  | Male | 11 | 7.9 | 139.9 | (69.7-250.3) |
| Female | 16 | 11.1 | 144.1 | (82.3-234.0) |  | Female | 7 | 5.4 | 130.1 | (52.1-268.0) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 7 | 4.8 | 146.7 | (58.8-302.3) |  | Male | 7 | 4.3 | 162.4 | (65.0-334.6) |
| Female | 4 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 18 | 13.4 | 134.8 | (79.8-213.0) |  | Male | 13 | 7.7 | 168.1 | (89.4-287.4) |
| Female | 8 | 10.8 | 74.4 | (32.0-146.6) |  | Female | 28 | 23.6 | 118.6 | (78.8-171.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 14 | 10.8 | 129.6 | (70.8-217.5) |  |  |  |  |  |  |
| Female | 2 | 4.0 | nc | (nc-nc) |  | Female | 33 | 29.9 | 110.3 | (75.9-154.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 64 | 61.0 | 104.9 | (80.8-134.0) |  | Male | 483 | 437.0 | 110.5 | (100.9-120.8) |
| Female | 83 | 69.1 | 120.2 | (95.7-149.0) |  | Female | 526 | 475.7 | 110.6 | (101.3-120.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

229

# Oak Bluffs

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 5.6 | 89.9 | (29.0-209.7) |  | Male | 10 | 3.6 | 277.2 | (132.7-509.7) |
| Female | 0 | 2.2 | nc | (nc-nc) |  | Female | 0 | 2.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 3 | 3.2 | nc | (nc-nc) |
| Female | 22 | 22.1 | 99.5 | (62.3-150.7) |  | Female | 1 | 2.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 2.6 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 6.1 | 97.8 | (35.7-212.9) |  |  |  |  |  |  |
| Female | 5 | 6.8 | 74.0 | (23.9-172.8) |  | Female | 2 | 2.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  | Male | 4 | 1.9 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 1 | 2.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 19 | 20.2 | 94.3 | (56.7-147.2) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 3.0 | nc | (nc-nc) |  | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 2.2 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 4 | 3.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 1.9 | 264.4 | (85.2-617.0) |  |  |  |  |  |  |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 7 | 5.1 | 137.9 | (55.2-284.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 10.1 | 49.4 | (15.9-115.3) |  | Male | 69 | 74.3 | 92.9 | (72.3-117.6) |
| Female | 12 | 11.1 | 108.4 | (55.9-189.3) |  | Female | 69 | 77.2 | 89.3 | (69.5-113.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

230

# Oakham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 2.0 | nc | (nc-nc) |  | Male | 0 | 1.4 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 6 | 7.7 | 77.5 | (28.3-168.6) |  | Female | 2 | 0.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 2.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.8 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 12 | 8.1 | 147.6 | (76.2-257.8) |
| Female | 1 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 2 | 0.5 | nc | (nc-nc) |
| Female | 2 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 0.8 | nc | (nc-nc) |  | Male | 2 | 0.6 | nc | (nc-nc) |
| Female | 2 | 0.5 | nc | (nc-nc) |  | Female | 0 | 1.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 3.7 | nc | (nc-nc) |  | Male | 26 | 28.7 | 90.5 | (59.1-132.6) |
| Female | 1 | 3.1 | nc | (nc-nc) |  | Female | 20 | 24.3 | 82.3 | (50.3-127.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

231

# Orange

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 10 | 8.6 | 115.7 | (55.4-212.8) |  | Male | 4 | 5.7 | nc | (nc-nc) |
| Female | 2 | 3.2 | nc | (nc-nc) |  | Female | 3 | 4.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 1.6 | nc | (nc-nc) |  | Male | 1 | 1.7 | nc | (nc-nc) |
| Female | 3 | 1.4 | nc | (nc-nc) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 7 | 5.0 | 140.3 | (56.2-289.0) |
| Female | 38 | 34.8 | 109.4 | (77.4-150.1) |  | Female | 3 | 4.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 4.1 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 9.6 | 73.1 | (29.3-150.7) |  |  |  |  |  |  |
| Female | 5 | 9.6 | 52.1 | (16.8-121.6) |  | Female | 1 | 3.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 2.4 | nc | (nc-nc) |  | Male | 2 | 3.0 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 1 | 3.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 34 | 32.5 | 104.8 | (72.5-146.4) |
| Female | 1 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 4.8 | 104.0 | (33.5-242.6) |  | Male | 0 | 2.0 | nc | (nc-nc) |
| Female | 3 | 2.8 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 3.4 | nc | (nc-nc) |  | Male | 2 | 2.2 | nc | (nc-nc) |
| Female | 0 | 2.5 | nc | (nc-nc) |  | Female | 7 | 6.4 | 109.4 | (43.8-225.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 3.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 13 | 8.0 | 163.3 | (86.9-279.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 19 | 15.9 | 119.5 | (71.9-186.6) |  | Male | 120 | 117.7 | 102.0 | (84.5-121.9) |
| Female | 12 | 16.7 | 71.8 | (37.0-125.4) |  | Female | 108 | 117.7 | 91.8 | (75.3-110.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

232

# Orleans

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 16 | 16.3 | 97.9 | (55.9-159.0) |  | Male | 22 | 8.8 | 249.5 | (156.3-377.8) |
| Female | 5 | 5.5 | 91.4 | (29.5-213.3) |  | Female | 10 | 5.6 | 177.0 | (84.7-325.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 2.0 | nc | (nc-nc) |  | Male | 3 | 2.8 | nc | (nc-nc) |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 1 | 2.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 10 | 7.7 | 129.1 | (61.8-237.4) |
| Female | 64 | 45.1 | 142.1 | (109.4-181.4) |  | Female | 5 | 6.5 | 76.9 | (24.8-179.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 5.3 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 4 | 2.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 15 | 15.8 | 95.2 | (53.2-157.0) |  |  |  |  |  |  |
| Female | 16 | 15.5 | 102.9 | (58.8-167.2) |  | Female | 3 | 4.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 3.8 | nc | (nc-nc) |  | Male | 2 | 5.2 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 6 | 5.4 | 111.5 | (40.7-242.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 42 | 48.4 | 86.8 | (62.5-117.3) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 6.7 | nc | (nc-nc) |  | Male | 2 | 3.5 | nc | (nc-nc) |
| Female | 2 | 4.0 | nc | (nc-nc) |  | Female | 2 | 2.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 5.4 | 128.8 | (51.6-265.4) |  | Male | 1 | 2.3 | nc | (nc-nc) |
| Female | 2 | 3.7 | nc | (nc-nc) |  | Female | 3 | 5.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 4.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 15 | 10.7 | 140.0 | (78.3-231.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 14 | 28.4 | 49.3 | (26.9-82.7) |  | Male | 162 | 185.5 | 87.3 | (74.4-101.8) |
| Female | 19 | 27.5 | 69.1 | (41.6-107.9) |  | Female | 175 | 167.4 | 104.6 | (89.6-121.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

233

# Otis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 2.5 | nc | (nc-nc) |  | Male | 2 | 1.6 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 2 | 1.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 10 | 8.3 | 121.2 | (58.0-222.9) |  | Female | 3 | 1.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 2.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 2.1 | nc | (nc-nc) |  | Female | 2 | 0.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 13 | 9.4 | 138.8 | (73.8-237.4) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 2 | 1.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 2.0 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 4.6 | 108.7 | (35.0-253.7) |  | Male | 29 | 33.2 | 87.4 | (58.5-125.5) |
| Female | 6 | 3.9 | 155.2 | (56.7-337.8) |  | Female | 29 | 27.0 | 107.2 | (71.8-154.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

234

# Oxford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 16 | 13.1 | 122.5 | (70.0-199.0) |  | Male | 9 | 9.0 | 100.3 | (45.8-190.3) |
| Female | 8 | 4.7 | 171.8 | (74.0-338.5) |  | Female | 7 | 7.4 | 95.2 | (38.1-196.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 2.7 | nc | (nc-nc) |  | Male | 2 | 2.6 | nc | (nc-nc) |
| Female | 1 | 2.3 | nc | (nc-nc) |  | Female | 3 | 2.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 10 | 7.9 | 126.0 | (60.3-231.8) |
| Female | 52 | 56.7 | 91.8 | (68.5-120.4) |  | Female | 6 | 6.6 | 91.5 | (33.4-199.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 6.7 | 119.4 | (51.4-235.2) |
| Female | 0 | 2.1 | nc | (nc-nc) |  | Female | 4 | 2.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 15.2 | 39.6 | (14.5-86.2) |  |  |  |  |  |  |
| Female | 16 | 14.5 | 110.3 | (63.0-179.1) |  | Female | 5 | 5.1 | 98.3 | (31.7-229.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 3.7 | nc | (nc-nc) |  | Male | 2 | 4.6 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 5 | 4.5 | 111.1 | (35.8-259.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 47 | 50.9 | 92.4 | (67.9-122.9) |
| Female | 2 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 7.8 | nc | (nc-nc) |  | Male | 2 | 3.2 | nc | (nc-nc) |
| Female | 6 | 4.4 | 137.6 | (50.2-299.4) |  | Female | 2 | 1.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 5 | 2.1 | 240.5 | (77.5-561.1) |  | Male | 4 | 2.0 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 5.4 | 184.5 | (88.3-339.3) |  | Male | 4 | 3.7 | nc | (nc-nc) |
| Female | 5 | 3.9 | 127.8 | (41.2-298.2) |  | Female | 10 | 11.3 | 88.6 | (42.4-163.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 4.9 | 143.4 | (57.5-295.6) |  |  |  |  |  |  |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 20 | 12.9 | 155.3 | (94.8-239.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 39 | 24.1 | 161.8 | (115.0-221.1) |  | Male | 192 | 184.6 | 104.0 | (89.8-119.8) |
| Female | 31 | 25.0 | 123.8 | (84.1-175.8) |  | Female | 201 | 185.8 | 108.2 | (93.8-124.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

235

# Palmer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 22 | 13.3 | 165.9 | (103.9-251.2) |  | Male | 12 | 8.7 | 137.2 | (70.8-239.7) |
| Female | 9 | 5.1 | 175.6 | (80.2-333.5) |  | Female | 8 | 7.0 | 113.8 | (49.0-224.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.5 | nc | (nc-nc) |  | Male | 0 | 2.6 | nc | (nc-nc) |
| Female | 1 | 2.1 | nc | (nc-nc) |  | Female | 1 | 2.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 7.8 | nc | (nc-nc) |
| Female | 60 | 53.4 | 112.4 | (85.8-144.7) |  | Female | 10 | 6.7 | 148.9 | (71.3-273.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 6.3 | 94.7 | (34.6-206.2) |
| Female | 2 | 1.8 | nc | (nc-nc) |  | Female | 0 | 2.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 9 | 15.0 | 60.1 | (27.4-114.0) |  |  |  |  |  |  |
| Female | 13 | 15.8 | 82.1 | (43.6-140.3) |  | Female | 4 | 4.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 3.6 | nc | (nc-nc) |  | Male | 6 | 4.5 | 132.1 | (48.2-287.5) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 8 | 5.0 | 158.7 | (68.3-312.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.1 | nc | (nc-nc) |  | Male | 36 | 48.1 | 74.9 | (52.4-103.6) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 7.3 | 108.9 | (46.9-214.5) |  | Male | 6 | 3.1 | 191.3 | (69.9-416.4) |
| Female | 3 | 4.3 | nc | (nc-nc) |  | Female | 2 | 2.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 5 | 2.0 | 250.5 | (80.7-584.5) |  | Male | 0 | 1.8 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 5.3 | nc | (nc-nc) |  | Male | 2 | 3.5 | nc | (nc-nc) |
| Female | 5 | 4.0 | 123.7 | (39.9-288.6) |  | Female | 7 | 9.7 | 71.8 | (28.8-148.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 4.7 | 107.4 | (34.6-250.7) |  |  |  |  |  |  |
| Female | 3 | 1.5 | nc | (nc-nc) |  | Female | 11 | 12.0 | 92.0 | (45.9-164.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 29 | 23.9 | 121.1 | (81.1-173.9) |  | Male | 171 | 179.3 | 95.4 | (81.6-110.8) |
| Female | 19 | 25.6 | 74.3 | (44.7-116.0) |  | Female | 180 | 183.6 | 98.0 | (84.2-113.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

236

# Paxton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 5.4 | nc | (nc-nc) |  | Male | 5 | 3.4 | 145.2 | (46.8-339.0) |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 1 | 2.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.0 | nc | (nc-nc) |  | Male | 2 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 3.1 | nc | (nc-nc) |
| Female | 22 | 19.1 | 115.4 | (72.3-174.7) |  | Female | 0 | 2.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 2.4 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 5.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 6 | 5.1 | 117.2 | (42.8-255.1) |  | Female | 2 | 1.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 1 | 1.8 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 24 | 19.1 | 125.4 | (80.3-186.7) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 2.9 | nc | (nc-nc) |  | Male | 2 | 1.3 | nc | (nc-nc) |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 2 | 0.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 2.1 | nc | (nc-nc) |  | Male | 4 | 1.3 | nc | (nc-nc) |
| Female | 2 | 1.4 | nc | (nc-nc) |  | Female | 2 | 3.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 5 | 4.4 | 114.6 | (36.9-267.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 7 | 9.7 | 71.9 | (28.8-148.1) |  | Male | 71 | 71.4 | 99.5 | (77.7-125.5) |
| Female | 6 | 8.8 | 67.8 | (24.8-147.7) |  | Female | 58 | 63.7 | 91.1 | (69.1-117.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

237

# Peabody

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 82 | 72.9 | 112.5 | (89.5-139.7) |  | Male | 38 | 43.6 | 87.2 | (61.7-119.7) |
| Female | 36 | 29.2 | 123.4 | (86.4-170.8) |  | Female | 36 | 35.2 | 102.3 | (71.6-141.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 12 | 11.5 | 103.9 | (53.6-181.6) |  | Male | 18 | 13.0 | 138.2 | (81.9-218.4) |
| Female | 12 | 10.8 | 111.3 | (57.4-194.4) |  | Female | 20 | 12.0 | 167.2 | (102.1-258.2) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 5 | 2.2 | 228.3 | (73.6-532.8) |  | Male | 46 | 38.7 | 118.8 | (87.0-158.4) |
| Female | 267 | 266.6 | 100.1 | (88.5-112.9) |  | Female | 53 | 36.2 | 146.4 | (109.6-191.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 37 | 28.5 | 129.7 | (91.3-178.8) |
| Female | 12 | 8.4 | 142.9 | (73.8-249.7) |  | Female | 14 | 14.6 | 96.2 | (52.5-161.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 72 | 76.4 | 94.2 | (73.7-118.7) |  |  |  |  |  |  |
| Female | 91 | 87.8 | 103.6 | (83.4-127.2) |  | Female | 21 | 24.9 | 84.2 | (52.1-128.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 15 | 17.8 | 84.3 | (47.2-139.1) |  | Male | 18 | 23.7 | 75.8 | (44.9-119.8) |
| Female | 4 | 5.5 | nc | (nc-nc) |  | Female | 34 | 28.8 | 118.0 | (81.7-164.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 4.5 | nc | (nc-nc) |  | Male | 272 | 226.1 | 120.3 | (106.4-135.5) |
| Female | 6 | 4.0 | 150.9 | (55.1-328.4) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 39 | 34.3 | 113.7 | (80.8-155.4) |  | Male | 13 | 16.3 | 79.7 | (42.4-136.3) |
| Female | 19 | 22.4 | 84.7 | (51.0-132.3) |  | Female | 9 | 11.2 | 80.1 | (36.6-152.1) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 17 | 9.7 | 175.8 | (102.3-281.4) |  | Male | 13 | 7.1 | 184.1 | (97.9-314.9) |
| Female | 2 | 3.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 30 | 27.1 | 110.7 | (74.7-158.1) |  | Male | 17 | 14.6 | 116.8 | (68.0-187.1) |
| Female | 30 | 21.7 | 138.0 | (93.1-197.0) |  | Female | 38 | 43.2 | 88.0 | (62.3-120.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 25 | 21.7 | 115.3 | (74.6-170.2) |  |  |  |  |  |  |
| Female | 9 | 8.2 | 110.1 | (50.2-209.0) |  | Female | 56 | 59.8 | 93.7 | (70.8-121.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 130 | 126.5 | 102.7 | (85.8-122.0) |  | Male | 996 | 888.9 | 112.0 | (105.2-119.2) |
| Female | 172 | 142.8 | 120.4 | (103.1-139.8) |  | Female | 1024 | 960.0 | 106.7 | (100.2-113.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

238

# Pelham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 2 | 0.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 6 | 6.9 | 87.5 | (32.0-190.5) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 2.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 7 | 7.2 | 97.4 | (39.0-200.6) |
| Female | 1 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 3.6 | nc | (nc-nc) |  | Male | 16 | 25.7 | 62.2 | (35.6-101.1) |
| Female | 0 | 3.2 | nc | (nc-nc) |  | Female | 12 | 22.6 | 53.2 | (27.4-92.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

239

# Pembroke

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 24 | 16.2 | 148.1 | (94.8-220.3) |  | Male | 15 | 11.4 | 131.8 | (73.7-217.4) |
| Female | 6 | 5.6 | 107.3 | (39.2-233.5) |  | Female | 11 | 9.2 | 119.4 | (59.5-213.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 3.5 | nc | (nc-nc) |  | Male | 2 | 3.3 | nc | (nc-nc) |
| Female | 2 | 2.9 | nc | (nc-nc) |  | Female | 0 | 2.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 15 | 10.0 | 150.2 | (84.0-247.7) |
| Female | 91 | 72.6 | 125.3 | (100.9-153.8) |  | Female | 6 | 8.1 | 74.0 | (27.0-161.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 8.6 | 93.0 | (40.1-183.3) |
| Female | 2 | 2.7 | nc | (nc-nc) |  | Female | 1 | 3.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 27 | 19.0 | 142.0 | (93.6-206.6) |  |  |  |  |  |  |
| Female | 19 | 17.4 | 109.0 | (65.6-170.2) |  | Female | 4 | 6.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 4.7 | nc | (nc-nc) |  | Male | 2 | 5.8 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 5 | 5.4 | 93.0 | (30.0-217.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  | Male | 74 | 65.5 | 113.1 | (88.8-141.9) |
| Female | 2 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 12 | 10.0 | 120.0 | (61.9-209.6) |  | Male | 3 | 4.0 | nc | (nc-nc) |
| Female | 6 | 5.5 | 109.7 | (40.1-238.8) |  | Female | 1 | 2.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 2.7 | nc | (nc-nc) |  | Male | 2 | 2.5 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 6.8 | 131.9 | (60.2-250.5) |  | Male | 3 | 4.8 | nc | (nc-nc) |
| Female | 6 | 4.8 | 125.1 | (45.7-272.3) |  | Female | 22 | 14.5 | 151.2 | (94.7-229.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 6.2 | 80.5 | (26.0-188.0) |  |  |  |  |  |  |
| Female | 0 | 1.8 | nc | (nc-nc) |  | Female | 17 | 16.6 | 102.5 | (59.7-164.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 36 | 30.5 | 117.9 | (82.6-163.2) |  | Male | 262 | 234.3 | 111.8 | (98.7-126.2) |
| Female | 44 | 30.9 | 142.5 | (103.5-191.3) |  | Female | 268 | 232.7 | 115.2 | (101.8-129.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

240

# Pepperell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 10.1 | 69.2 | (27.7-142.5) |  | Male | 8 | 7.3 | 109.8 | (47.3-216.4) |
| Female | 2 | 3.5 | nc | (nc-nc) |  | Female | 2 | 5.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 2.3 | nc | (nc-nc) |  | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 2 | 1.8 | nc | (nc-nc) |  | Female | 2 | 1.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 8 | 6.4 | 124.5 | (53.6-245.4) |
| Female | 47 | 46.3 | 101.6 | (74.7-135.1) |  | Female | 5 | 5.1 | 98.8 | (31.8-230.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 5.7 | nc | (nc-nc) |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 4 | 2.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 12.2 | 81.7 | (39.1-150.3) |  |  |  |  |  |  |
| Female | 16 | 11.0 | 145.9 | (83.3-236.9) |  | Female | 2 | 4.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 3.0 | 164.6 | (53.0-384.1) |  | Male | 3 | 3.7 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 5 | 3.3 | 150.3 | (48.4-350.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.0 | nc | (nc-nc) |  | Male | 36 | 42.4 | 84.9 | (59.5-117.6) |
| Female | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 6.5 | 92.6 | (33.8-201.5) |  | Male | 3 | 2.5 | nc | (nc-nc) |
| Female | 3 | 3.4 | nc | (nc-nc) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.7 | nc | (nc-nc) |  | Male | 2 | 1.6 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 4.4 | 160.6 | (64.3-330.9) |  | Male | 6 | 3.2 | 187.7 | (68.5-408.6) |
| Female | 5 | 3.0 | 167.1 | (53.8-389.9) |  | Female | 4 | 9.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 4.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 11 | 10.6 | 104.1 | (51.9-186.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 19 | 19.1 | 99.5 | (59.9-155.4) |  | Male | 147 | 150.5 | 97.7 | (82.5-114.8) |
| Female | 16 | 19.0 | 84.2 | (48.1-136.7) |  | Female | 138 | 146.7 | 94.1 | (79.0-111.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

241

# Peru

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 3.3 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 3.9 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 1.7 | nc | (nc-nc) |  | Male | 10 | 13.2 | 75.6 | (36.2-139.1) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 4 | 10.2 | nc | (nc-nc) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

242

# Petersham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 4 | 6.2 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 4 | 6.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 1 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 2 | 0.4 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 3 | 1.5 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 3.3 | nc | (nc-nc) |  | Male | 13 | 23.8 | 54.7 | (29.1-93.5) |
| Female | 0 | 3.0 | nc | (nc-nc) |  | Female | 15 | 20.7 | 72.6 | (40.6-119.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

243

# Phillipston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 1.6 | nc | (nc-nc) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 5 | 6.5 | 76.5 | (24.6-178.4) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 2 | 0.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 7 | 6.7 | 104.1 | (41.7-214.5) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 4 | 1.5 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 3.0 | nc | (nc-nc) |  | Male | 17 | 23.8 | 71.4 | (41.6-114.4) |
| Female | 3 | 2.6 | nc | (nc-nc) |  | Female | 18 | 20.2 | 88.9 | (52.7-140.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

244

# Pittsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 57 | 57.2 | 99.6 | (75.4-129.0) |  | Male | 29 | 35.3 | 82.1 | (54.9-117.9) |
| Female | 26 | 21.6 | 120.1 | (78.5-176.0) |  | Female | 31 | 27.9 | 111.1 | (75.4-157.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 15 | 9.7 | 154.0 | (86.1-254.1) |  | Male | 9 | 10.5 | 85.7 | (39.1-162.7) |
| Female | 7 | 8.7 | 80.9 | (32.4-166.7) |  | Female | 5 | 9.0 | 55.5 | (17.9-129.5) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 34 | 31.3 | 108.7 | (75.2-151.8) |
| Female | 210 | 211.9 | 99.1 | (86.2-113.5) |  | Female | 33 | 27.7 | 119.3 | (82.1-167.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 28 | 23.9 | 117.1 | (77.8-169.2) |
| Female | 9 | 6.9 | 129.7 | (59.2-246.3) |  | Female | 6 | 11.3 | 53.2 | (19.4-115.8) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 64 | 61.0 | 104.9 | (80.7-133.9) |  |  |  |  |  |  |
| Female | 86 | 65.2 | 131.9 | (105.5-162.9) |  | Female | 15 | 19.7 | 76.3 | (42.7-125.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 26 | 14.5 | 178.8 | (116.8-262.0) |  | Male | 19 | 19.0 | 100.2 | (60.3-156.5) |
| Female | 4 | 4.1 | nc | (nc-nc) |  | Female | 15 | 21.2 | 70.6 | (39.5-116.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 3.9 | nc | (nc-nc) |  | Male | 179 | 188.8 | 94.8 | (81.4-109.8) |
| Female | 2 | 3.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 30 | 28.5 | 105.2 | (71.0-150.2) |  | Male | 7 | 13.0 | 53.8 | (21.5-110.8) |
| Female | 21 | 17.5 | 120.1 | (74.3-183.7) |  | Female | 4 | 8.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 7 | 8.0 | 87.8 | (35.2-180.9) |  | Male | 9 | 6.3 | 143.5 | (65.5-272.4) |
| Female | 3 | 2.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 19 | 21.9 | 86.9 | (52.3-135.7) |  | Male | 14 | 12.5 | 112.2 | (61.3-188.3) |
| Female | 9 | 16.7 | 54.0 | (24.7-102.6) |  | Female | 24 | 36.4 | 65.9 | (42.2-98.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 21 | 18.1 | 116.3 | (72.0-177.8) |  |  |  |  |  |  |
| Female | 7 | 6.3 | 111.9 | (44.8-230.6) |  | Female | 43 | 48.0 | 89.5 | (64.8-120.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 112 | 101.4 | 110.5 | (90.9-132.9) |  | Male | 741 | 724.1 | 102.3 | (95.1-110.0) |
| Female | 144 | 108.7 | 132.4 | (111.7-155.9) |  | Female | 759 | 745.4 | 101.8 | (94.7-109.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

245

# Plainfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 1 | 3.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 2 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 3.8 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 1 | 0.2 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 1.8 | 277.4 | (89.4-647.3) |  | Male | 14 | 13.1 | 107.0 | (58.5-179.6) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 8 | 10.4 | 76.7 | (33.0-151.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

246

# Plainville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 12 | 8.1 | 148.8 | (76.8-260.0) |  | Male | 5 | 5.5 | 91.4 | (29.4-213.2) |
| Female | 2 | 3.1 | nc | (nc-nc) |  | Female | 2 | 4.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.6 | nc | (nc-nc) |  | Male | 2 | 1.6 | nc | (nc-nc) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.3 | nc | (nc-nc) |  | Male | 9 | 4.8 | 186.5 | (85.1-354.1) |
| Female | 32 | 35.5 | 90.2 | (61.7-127.4) |  | Female | 3 | 4.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 4.0 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 4 | 1.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 8 | 9.1 | 87.5 | (37.7-172.4) |  |  |  |  |  |  |
| Female | 10 | 9.4 | 106.1 | (50.8-195.1) |  | Female | 4 | 3.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 2.2 | nc | (nc-nc) |  | Male | 6 | 2.8 | 214.7 | (78.4-467.3) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 4 | 3.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 33 | 30.5 | 108.1 | (74.4-151.9) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 4.7 | 213.4 | (102.2-392.5) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 2 | 2.8 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 3.3 | nc | (nc-nc) |  | Male | 3 | 2.2 | nc | (nc-nc) |
| Female | 5 | 2.5 | 198.8 | (64.1-463.9) |  | Female | 7 | 6.8 | 102.7 | (41.2-211.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 7 | 8.0 | 87.4 | (35.0-180.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 14 | 14.9 | 93.9 | (51.3-157.5) |  | Male | 131 | 112.0 | 116.9 | (97.8-138.8) |
| Female | 18 | 16.6 | 108.4 | (64.2-171.3) |  | Female | 117 | 118.4 | 98.8 | (81.7-118.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

247

# Plymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 72 | 60.0 | 120.0 | (93.9-151.1) |  | Male | 62 | 40.1 | 154.7 | (118.6-198.4) |
| Female | 21 | 22.2 | 94.5 | (58.5-144.5) |  | Female | 63 | 32.3 | 195.2 | (150.0-249.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 10 | 11.8 | 85.0 | (40.7-156.4) |  | Male | 13 | 11.7 | 111.3 | (59.2-190.4) |
| Female | 11 | 10.0 | 109.9 | (54.8-196.7) |  | Female | 8 | 9.6 | 83.5 | (35.9-164.5) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 1.9 | nc | (nc-nc) |  | Male | 43 | 35.2 | 122.1 | (88.3-164.4) |
| Female | 296 | 249.6 | 118.6 | (105.5-132.9) |  | Female | 35 | 30.2 | 115.8 | (80.7-161.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 38 | 29.2 | 130.3 | (92.2-178.9) |
| Female | 4 | 8.8 | nc | (nc-nc) |  | Female | 13 | 12.7 | 102.2 | (54.4-174.8) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 84 | 67.2 | 124.9 | (99.7-154.7) |  |  |  |  |  |  |
| Female | 82 | 67.4 | 121.6 | (96.7-150.9) |  | Female | 26 | 22.8 | 114.1 | (74.5-167.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 23 | 16.8 | 137.3 | (87.0-206.0) |  | Male | 23 | 20.9 | 110.3 | (69.9-165.5) |
| Female | 1 | 4.3 | nc | (nc-nc) |  | Female | 20 | 21.7 | 92.0 | (56.2-142.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 5.0 | nc | (nc-nc) |  | Male | 264 | 229.7 | 115.0 | (101.5-129.7) |
| Female | 3 | 3.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 31 | 34.3 | 90.4 | (61.4-128.3) |  | Male | 17 | 14.3 | 119.2 | (69.4-190.8) |
| Female | 20 | 19.7 | 101.8 | (62.1-157.2) |  | Female | 9 | 8.5 | 106.5 | (48.6-202.1) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 13 | 9.3 | 140.1 | (74.5-239.5) |  | Male | 3 | 8.5 | nc | (nc-nc) |
| Female | 1 | 3.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 33 | 24.2 | 136.3 | (93.8-191.4) |  | Male | 17 | 16.0 | 106.0 | (61.7-169.8) |
| Female | 16 | 17.8 | 89.7 | (51.2-145.6) |  | Female | 70 | 46.2 | 151.5 | (118.1-191.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 21 | 21.3 | 98.8 | (61.1-151.1) |  |  |  |  |  |  |
| Female | 5 | 6.9 | 72.9 | (23.5-170.2) |  | Female | 58 | 58.4 | 99.4 | (75.5-128.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 113 | 110.6 | 102.2 | (84.2-122.9) |  | Male | 956 | 829.1 | 115.3 | (108.1-122.9) |
| Female | 123 | 116.1 | 105.9 | (88.0-126.4) |  | Female | 961 | 837.5 | 114.7 | (107.6-122.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

248

# Plympton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 3.2 | nc | (nc-nc) |  | Male | 2 | 2.2 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 3 | 1.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 9 | 12.6 | 71.2 | (32.5-135.3) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 2 | 0.4 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 3.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 3.0 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 15 | 13.4 | 112.1 | (62.7-184.9) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 1.9 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 1 | 2.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 3.0 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 6.1 | nc | (nc-nc) |  | Male | 38 | 45.8 | 83.0 | (58.7-113.9) |
| Female | 7 | 5.4 | 128.6 | (51.5-265.0) |  | Female | 39 | 40.3 | 96.8 | (68.8-132.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

249

# Princeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 3.8 | 158.7 | (58.0-345.5) |  | Male | 2 | 2.7 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 1 | 1.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 2.3 | nc | (nc-nc) |
| Female | 14 | 15.6 | 89.7 | (49.0-150.5) |  | Female | 3 | 1.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 2.1 | 233.7 | (75.3-545.3) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 4.5 | 111.8 | (36.0-261.0) |  |  |  |  |  |  |
| Female | 1 | 3.7 | nc | (nc-nc) |  | Female | 6 | 1.4 | 430.1 | (157.0-936.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 1.2 | nc | (nc-nc) |  | Male | 2 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 24 | 16.7 | 143.8 | (92.1-213.9) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 2.4 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 5 | 1.2 | 431.7 | (139.1-1007.5) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 1.5 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 3 | 2.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 3 | 3.7 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 7.3 | nc | (nc-nc) |  | Male | 63 | 56.4 | 111.8 | (85.9-143.0) |
| Female | 3 | 6.5 | nc | (nc-nc) |  | Female | 49 | 49.3 | 99.3 | (73.5-131.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

250

# Provincetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 5.2 | nc | (nc-nc) |  | Male | 7 | 3.4 | 205.6 | (82.4-423.7) |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 3 | 2.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 2 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 3 | 3.0 | nc | (nc-nc) |
| Female | 23 | 16.8 | 137.2 | (87.0-205.9) |  | Female | 1 | 2.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 2.6 | 194.1 | (62.5-452.9) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 5.9 | 101.3 | (37.0-220.4) |  |  |  |  |  |  |
| Female | 5 | 4.7 | 106.1 | (34.2-247.6) |  | Female | 2 | 1.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 2 | 1.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 0.3 | nc | (nc-nc) |  | Male | 14 | 20.1 | 69.8 | (38.1-117.1) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 2.9 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.9 | nc | (nc-nc) |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 2 | 1.1 | nc | (nc-nc) |  | Female | 1 | 2.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 4 | 4.1 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 11 | 9.5 | 115.8 | (57.7-207.3) |  | Male | 77 | 71.0 | 108.4 | (85.5-135.5) |
| Female | 10 | 8.4 | 119.4 | (57.1-219.5) |  | Female | 68 | 56.8 | 119.7 | (93.0-151.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

251

# Quincy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 81 | 98.3 | 82.4 | (65.4-102.4) |  | Male | 49 | 64.0 | 76.6 | (56.7-101.3) |
| Female | 31 | 39.7 | 78.2 | (53.1-111.0) |  | Female | 64 | 55.6 | 115.1 | (88.6-147.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 16 | 18.4 | 87.0 | (49.7-141.3) |  | Male | 16 | 18.5 | 86.6 | (49.4-140.6) |
| Female | 11 | 16.7 | 66.0 | (32.9-118.0) |  | Female | 10 | 16.6 | 60.1 | (28.8-110.6) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 3.1 | nc | (nc-nc) |  | Male | 49 | 56.4 | 86.8 | (64.2-114.8) |
| Female | 380 | 403.4 | 94.2 | (85.0-104.2) |  | Female | 58 | 51.9 | 111.7 | (84.8-144.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 61 | 44.0 | 138.8 | (106.1-178.3) |
| Female | 19 | 14.5 | 130.7 | (78.6-204.1) |  | Female | 22 | 21.2 | 103.5 | (64.9-156.8) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 137 | 107.8 | 127.0 | (106.7-150.2) |  |  |  |  |  |  |
| Female | 117 | 121.0 | 96.7 | (80.0-115.9) |  | Female | 37 | 37.5 | 98.5 | (69.4-135.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 30 | 25.7 | 116.5 | (78.6-166.4) |  | Male | 30 | 33.2 | 90.5 | (61.0-129.2) |
| Female | 9 | 7.5 | 119.5 | (54.5-226.8) |  | Female | 37 | 39.0 | 95.0 | (66.9-130.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 7 | 8.5 | 82.8 | (33.2-170.6) |  | Male | 297 | 339.5 | 87.5 | (77.8-98.0) |
| Female | 7 | 7.3 | 95.4 | (38.2-196.6) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 51 | 52.4 | 97.4 | (72.5-128.1) |  | Male | 25 | 22.9 | 109.4 | (70.8-161.5) |
| Female | 39 | 32.8 | 118.8 | (84.4-162.4) |  | Female | 11 | 15.4 | 71.7 | (35.7-128.2) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 14 | 14.2 | 98.6 | (53.8-165.4) |  | Male | 13 | 15.5 | 83.8 | (44.6-143.3) |
| Female | 7 | 5.0 | 140.9 | (56.4-290.3) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 26 | 39.0 | 66.7 | (43.5-97.7) |  | Male | 20 | 24.9 | 80.2 | (49.0-123.9) |
| Female | 28 | 31.3 | 89.4 | (59.4-129.3) |  | Female | 75 | 77.9 | 96.3 | (75.7-120.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 58 | 32.4 | 178.8 | (135.8-231.2) |  |  |  |  |  |  |
| Female | 13 | 11.6 | 112.3 | (59.7-192.0) |  | Female | 87 | 91.0 | 95.6 | (76.5-117.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 214 | 175.9 | 121.7 | (105.9-139.1) |  | Male | 1290 | 1295.2 | 99.6 | (94.2-105.2) |
| Female | 239 | 199.3 | 119.9 | (105.2-136.2) |  | Female | 1413 | 1412.7 | 100.0 | (94.9-105.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

252

# Randolph

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 36 | 32.3 | 111.4 | (78.0-154.2) |  | Male | 13 | 21.4 | 60.7 | (32.3-103.8) |
| Female | 6 | 12.6 | 47.8 | (17.5-104.0) |  | Female | 18 | 18.4 | 97.7 | (57.9-154.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 6.3 | 94.7 | (34.6-206.1) |  | Male | 5 | 6.2 | 80.3 | (25.9-187.4) |
| Female | 7 | 5.6 | 124.1 | (49.7-255.7) |  | Female | 9 | 5.4 | 167.5 | (76.4-318.1) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.0 | nc | (nc-nc) |  | Male | 17 | 18.9 | 90.0 | (52.4-144.1) |
| Female | 120 | 139.0 | 86.3 | (71.6-103.2) |  | Female | 17 | 17.0 | 100.2 | (58.3-160.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 15.4 | 32.4 | (10.5-75.7) |
| Female | 9 | 5.0 | 180.8 | (82.5-343.3) |  | Female | 8 | 7.1 | 112.6 | (48.5-221.9) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 40 | 36.2 | 110.5 | (78.9-150.4) |  |  |  |  |  |  |
| Female | 42 | 38.5 | 109.1 | (78.6-147.4) |  | Female | 10 | 12.7 | 78.6 | (37.6-144.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 8.8 | 68.0 | (24.8-148.1) |  | Male | 13 | 11.1 | 116.7 | (62.1-199.5) |
| Female | 3 | 2.4 | nc | (nc-nc) |  | Female | 11 | 12.2 | 90.1 | (44.9-161.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 2.8 | nc | (nc-nc) |  | Male | 123 | 119.1 | 103.3 | (85.8-123.2) |
| Female | 0 | 2.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 22 | 18.0 | 122.1 | (76.5-184.8) |  | Male | 7 | 7.6 | 91.7 | (36.7-188.9) |
| Female | 10 | 11.0 | 90.9 | (43.5-167.1) |  | Female | 6 | 4.8 | 124.3 | (45.4-270.5) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 7 | 4.9 | 143.0 | (57.3-294.7) |  | Male | 0 | 4.7 | nc | (nc-nc) |
| Female | 0 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 13 | 13.1 | 99.1 | (52.7-169.5) |  | Male | 4 | 8.5 | nc | (nc-nc) |
| Female | 5 | 10.2 | 49.2 | (15.9-114.9) |  | Female | 24 | 26.8 | 89.6 | (57.4-133.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 15 | 11.3 | 132.2 | (73.9-218.0) |  |  |  |  |  |  |
| Female | 7 | 3.8 | 183.3 | (73.4-377.7) |  | Female | 31 | 31.7 | 97.8 | (66.5-138.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 54 | 58.9 | 91.7 | (68.9-119.7) |  | Male | 414 | 440.0 | 94.1 | (85.2-103.6) |
| Female | 53 | 65.1 | 81.4 | (60.9-106.4) |  | Female | 431 | 470.6 | 91.6 | (83.1-100.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

253

# Raynham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 17 | 14.4 | 117.8 | (68.6-188.6) |  | Male | 7 | 9.5 | 74.1 | (29.7-152.6) |
| Female | 6 | 5.2 | 116.2 | (42.4-252.9) |  | Female | 11 | 7.5 | 146.2 | (72.9-261.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 2.8 | nc | (nc-nc) |  | Male | 3 | 2.8 | nc | (nc-nc) |
| Female | 3 | 2.3 | nc | (nc-nc) |  | Female | 4 | 2.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 8 | 8.4 | 95.8 | (41.2-188.7) |
| Female | 59 | 58.3 | 101.2 | (77.0-130.5) |  | Female | 8 | 7.0 | 113.7 | (49.0-224.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 6.8 | nc | (nc-nc) |
| Female | 5 | 2.1 | 242.9 | (78.3-566.9) |  | Female | 2 | 3.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 16 | 16.0 | 99.7 | (57.0-161.9) |  |  |  |  |  |  |
| Female | 19 | 15.8 | 120.4 | (72.5-188.0) |  | Female | 4 | 5.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 3.9 | 127.3 | (41.0-297.2) |  | Male | 6 | 4.9 | 121.5 | (44.4-264.4) |
| Female | 4 | 1.0 | nc | (nc-nc) |  | Female | 2 | 5.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 1.1 | nc | (nc-nc) |  | Male | 53 | 52.8 | 100.4 | (75.2-131.3) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 11 | 8.0 | 137.6 | (68.6-246.2) |  | Male | 3 | 3.4 | nc | (nc-nc) |
| Female | 9 | 4.6 | 196.6 | (89.7-373.2) |  | Female | 4 | 2.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.2 | nc | (nc-nc) |  | Male | 9 | 1.8 | 489.3 | (223.3-928.9) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 5.8 | 86.5 | (27.9-201.9) |  | Male | 6 | 3.7 | 163.7 | (59.8-356.2) |
| Female | 6 | 4.2 | 143.6 | (52.5-312.7) |  | Female | 22 | 10.9 | 201.1 | (126.0-304.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 5.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 11 | 13.3 | 82.5 | (41.2-147.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 33 | 26.3 | 125.5 | (86.4-176.3) |  | Male | 215 | 194.7 | 110.4 | (96.2-126.2) |
| Female | 33 | 27.1 | 121.8 | (83.8-171.1) |  | Female | 235 | 195.2 | 120.4 | (105.5-136.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

254

# Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 31 | 26.4 | 117.2 | (79.6-166.4) |  | Male | 25 | 17.3 | 144.8 | (93.7-213.7) |
| Female | 6 | 10.2 | 59.0 | (21.6-128.5) |  | Female | 15 | 14.3 | 105.1 | (58.8-173.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 5.1 | 118.2 | (43.2-257.3) |  | Male | 4 | 5.1 | nc | (nc-nc) |
| Female | 5 | 4.4 | 112.7 | (36.3-263.0) |  | Female | 4 | 4.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 17 | 15.3 | 111.1 | (64.7-177.8) |
| Female | 130 | 110.0 | 118.2 | (98.8-140.4) |  | Female | 9 | 13.5 | 66.6 | (30.4-126.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 12.3 | 48.6 | (17.8-105.8) |
| Female | 2 | 3.8 | nc | (nc-nc) |  | Female | 5 | 5.6 | 88.8 | (28.6-207.1) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 31 | 29.6 | 104.9 | (71.2-148.9) |  |  |  |  |  |  |
| Female | 31 | 31.3 | 99.0 | (67.3-140.6) |  | Female | 9 | 10.0 | 90.0 | (41.1-170.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 11 | 7.1 | 155.2 | (77.4-277.7) |  | Male | 10 | 9.0 | 111.0 | (53.1-204.1) |
| Female | 3 | 1.9 | nc | (nc-nc) |  | Female | 7 | 9.9 | 70.5 | (28.3-145.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 2.1 | nc | (nc-nc) |  | Male | 74 | 94.1 | 78.6 | (61.7-98.7) |
| Female | 4 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 9 | 14.5 | 62.1 | (28.4-118.0) |  | Male | 6 | 6.2 | 96.4 | (35.2-209.9) |
| Female | 4 | 8.7 | nc | (nc-nc) |  | Female | 2 | 3.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 3.9 | nc | (nc-nc) |  | Male | 2 | 3.3 | nc | (nc-nc) |
| Female | 0 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 12 | 10.6 | 112.7 | (58.2-197.0) |  | Male | 9 | 6.7 | 134.9 | (61.6-256.2) |
| Female | 11 | 8.2 | 134.8 | (67.2-241.2) |  | Female | 32 | 20.2 | 158.1 | (108.1-223.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 9 | 9.1 | 98.9 | (45.1-187.7) |  |  |  |  |  |  |
| Female | 6 | 3.0 | 197.2 | (72.0-429.3) |  | Female | 31 | 24.7 | 125.3 | (85.1-177.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 45 | 47.6 | 94.5 | (68.9-126.4) |  | Male | 329 | 353.5 | 93.1 | (83.3-103.7) |
| Female | 50 | 52.0 | 96.2 | (71.4-126.9) |  | Female | 407 | 373.2 | 109.1 | (98.7-120.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

255

# Rehoboth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 10 | 12.4 | 80.4 | (38.5-147.9) |  | Male | 8 | 8.5 | 94.2 | (40.6-185.6) |
| Female | 3 | 3.9 | nc | (nc-nc) |  | Female | 3 | 6.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 2.5 | nc | (nc-nc) |  | Male | 2 | 2.5 | nc | (nc-nc) |
| Female | 3 | 1.9 | nc | (nc-nc) |  | Female | 2 | 1.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 6 | 7.5 | 80.4 | (29.4-175.0) |
| Female | 48 | 50.1 | 95.8 | (70.6-127.0) |  | Female | 7 | 5.6 | 124.1 | (49.7-255.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 6.5 | nc | (nc-nc) |
| Female | 0 | 1.8 | nc | (nc-nc) |  | Female | 2 | 2.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 11 | 14.3 | 76.8 | (38.3-137.4) |  |  |  |  |  |  |
| Female | 12 | 12.3 | 97.7 | (50.4-170.6) |  | Female | 2 | 4.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 3.6 | nc | (nc-nc) |  | Male | 2 | 4.4 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 5 | 3.8 | 131.7 | (42.4-307.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 47 | 50.4 | 93.2 | (68.5-123.9) |
| Female | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 7.5 | 107.3 | (46.2-211.4) |  | Male | 1 | 3.0 | nc | (nc-nc) |
| Female | 6 | 3.8 | 158.3 | (57.8-344.6) |  | Female | 0 | 1.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.0 | nc | (nc-nc) |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 5.0 | nc | (nc-nc) |  | Male | 1 | 3.5 | nc | (nc-nc) |
| Female | 3 | 3.3 | nc | (nc-nc) |  | Female | 9 | 9.6 | 94.1 | (42.9-178.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 4.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 16 | 11.6 | 137.8 | (78.7-223.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 28 | 23.3 | 120.0 | (79.7-173.4) |  | Male | 144 | 177.5 | 81.1 | (68.4-95.5) |
| Female | 18 | 21.6 | 83.2 | (49.3-131.5) |  | Female | 151 | 161.1 | 93.7 | (79.4-109.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

256

# Revere

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 47 | 54.8 | 85.7 | (63.0-114.0) |  | Male | 22 | 35.3 | 62.4 | (39.1-94.4) |
| Female | 19 | 20.7 | 91.8 | (55.2-143.4) |  | Female | 26 | 29.0 | 89.6 | (58.5-131.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 13 | 10.3 | 126.7 | (67.4-216.7) |  | Male | 10 | 10.2 | 98.0 | (46.9-180.2) |
| Female | 8 | 8.9 | 89.7 | (38.6-176.8) |  | Female | 12 | 8.7 | 138.2 | (71.3-241.3) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.7 | nc | (nc-nc) |  | Male | 31 | 31.3 | 99.1 | (67.3-140.7) |
| Female | 214 | 212.3 | 100.8 | (87.7-115.2) |  | Female | 28 | 27.2 | 103.0 | (68.4-148.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 24 | 23.8 | 100.8 | (64.5-149.9) |
| Female | 5 | 7.6 | 65.7 | (21.2-153.3) |  | Female | 12 | 11.1 | 108.1 | (55.8-188.8) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 73 | 59.8 | 122.1 | (95.7-153.6) |  |  |  |  |  |  |
| Female | 43 | 63.3 | 67.9 | (49.1-91.5) |  | Female | 14 | 19.7 | 71.2 | (38.9-119.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 8 | 14.1 | 56.8 | (24.5-112.0) |  | Male | 17 | 18.3 | 92.8 | (54.0-148.6) |
| Female | 5 | 3.9 | 126.7 | (40.8-295.7) |  | Female | 15 | 20.4 | 73.7 | (41.2-121.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 7 | 4.7 | 148.3 | (59.4-305.6) |  | Male | 120 | 183.3 | 65.5 | (54.3-78.3) |
| Female | 4 | 3.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 36 | 28.6 | 125.8 | (88.1-174.1) |  | Male | 23 | 12.6 | 181.9 | (115.2-272.9) |
| Female | 35 | 17.3 | 202.4 | (140.9-281.5) |  | Female | 6 | 8.0 | 74.9 | (27.3-163.0) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 10 | 7.7 | 129.2 | (61.9-237.6) |  | Male | 9 | 8.5 | 105.3 | (48.0-199.9) |
| Female | 8 | 2.6 | 308.0 | (132.6-606.8) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 30 | 21.9 | 137.2 | (92.5-195.9) |  | Male | 13 | 13.6 | 95.8 | (50.9-163.8) |
| Female | 12 | 16.6 | 72.1 | (37.2-125.9) |  | Female | 47 | 40.8 | 115.1 | (84.6-153.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 32 | 17.6 | 182.0 | (124.5-256.9) |  |  |  |  |  |  |
| Female | 5 | 6.1 | 82.5 | (26.6-192.6) |  | Female | 39 | 47.5 | 82.0 | (58.3-112.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 127 | 97.3 | 130.6 | (108.8-155.3) |  | Male | 707 | 711.8 | 99.3 | (92.1-106.9) |
| Female | 143 | 104.5 | 136.8 | (115.3-161.2) |  | Female | 758 | 741.2 | 102.3 | (95.1-109.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

257

# Richmond

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 2.7 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 6 | 8.6 | 69.5 | (25.4-151.4) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 2.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 2.3 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 2 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 13 | 10.2 | 127.1 | (67.6-217.4) |
| Female | 1 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 2 | 1.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 2.1 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 5.1 | nc | (nc-nc) |  | Male | 28 | 35.6 | 78.8 | (52.3-113.8) |
| Female | 2 | 4.2 | nc | (nc-nc) |  | Female | 21 | 28.7 | 73.2 | (45.3-112.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

258

# Rochester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 5.4 | nc | (nc-nc) |  | Male | 4 | 3.7 | nc | (nc-nc) |
| Female | 3 | 1.7 | nc | (nc-nc) |  | Female | 3 | 2.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 2 | 3.3 | nc | (nc-nc) |
| Female | 26 | 22.1 | 117.5 | (76.7-172.1) |  | Female | 3 | 2.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 2.9 | nc | (nc-nc) |
| Female | 2 | 0.8 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 6.3 | 79.3 | (25.6-185.1) |  |  |  |  |  |  |
| Female | 6 | 5.2 | 114.4 | (41.8-249.0) |  | Female | 2 | 2.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 2 | 1.9 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 29 | 22.7 | 127.7 | (85.5-183.4) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 3.3 | nc | (nc-nc) |  | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 3 | 1.6 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 2.2 | nc | (nc-nc) |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 2 | 4.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 2.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 3 | 5.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 12 | 10.1 | 118.5 | (61.2-207.0) |  | Male | 73 | 78.6 | 92.9 | (72.8-116.8) |
| Female | 3 | 9.1 | nc | (nc-nc) |  | Female | 65 | 70.1 | 92.7 | (71.5-118.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

259

# Rockland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 22 | 17.4 | 126.2 | (79.1-191.1) |  | Male | 9 | 11.5 | 78.0 | (35.6-148.0) |
| Female | 12 | 7.0 | 172.3 | (88.9-301.0) |  | Female | 17 | 10.0 | 169.2 | (98.5-271.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 8 | 3.4 | 233.5 | (100.5-460.1) |  | Male | 2 | 3.3 | nc | (nc-nc) |
| Female | 4 | 3.1 | nc | (nc-nc) |  | Female | 0 | 3.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 12 | 10.2 | 117.6 | (60.7-205.5) |
| Female | 79 | 76.3 | 103.6 | (82.0-129.1) |  | Female | 13 | 9.3 | 139.1 | (74.0-237.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 8.3 | 120.9 | (57.9-222.3) |
| Female | 1 | 2.7 | nc | (nc-nc) |  | Female | 6 | 3.9 | 154.2 | (56.3-335.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 25 | 19.6 | 127.8 | (82.7-188.7) |  |  |  |  |  |  |
| Female | 28 | 21.3 | 131.5 | (87.4-190.1) |  | Female | 4 | 7.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 4.7 | 105.9 | (34.1-247.1) |  | Male | 7 | 6.0 | 117.0 | (46.9-241.1) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 7 | 6.8 | 103.3 | (41.4-213.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  | Male | 70 | 63.2 | 110.8 | (86.4-140.0) |
| Female | 0 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 12 | 9.7 | 123.8 | (63.9-216.2) |  | Male | 3 | 4.1 | nc | (nc-nc) |
| Female | 15 | 6.1 | 247.0 | (138.1-407.4) |  | Female | 5 | 2.7 | 187.3 | (60.4-437.1) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.6 | nc | (nc-nc) |  | Male | 4 | 2.5 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 13 | 7.1 | 183.0 | (97.4-313.0) |  | Male | 3 | 4.6 | nc | (nc-nc) |
| Female | 13 | 5.6 | 230.7 | (122.7-394.6) |  | Female | 22 | 14.5 | 152.1 | (95.3-230.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 6.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 2.1 | nc | (nc-nc) |  | Female | 22 | 17.2 | 127.6 | (79.9-193.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 38 | 31.6 | 120.3 | (85.1-165.1) |  | Male | 274 | 236.0 | 116.1 | (102.7-130.7) |
| Female | 55 | 36.3 | 151.7 | (114.3-197.5) |  | Female | 329 | 258.9 | 127.1 | (113.7-141.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

260

# Rockport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 10.9 | 100.6 | (50.2-180.0) |  | Male | 9 | 6.6 | 135.6 | (61.9-257.4) |
| Female | 3 | 4.4 | nc | (nc-nc) |  | Female | 8 | 5.4 | 148.3 | (63.9-292.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.7 | nc | (nc-nc) |  | Male | 1 | 2.0 | nc | (nc-nc) |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 3 | 1.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 0.3 | nc | (nc-nc) |  | Male | 6 | 5.8 | 103.1 | (37.7-224.4) |
| Female | 42 | 43.2 | 97.3 | (70.1-131.5) |  | Female | 7 | 5.6 | 124.7 | (49.9-256.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 4.7 | 149.8 | (60.0-308.6) |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 5 | 2.3 | 215.6 | (69.5-503.1) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 8 | 11.5 | 69.4 | (29.9-136.8) |  |  |  |  |  |  |
| Female | 12 | 13.0 | 92.0 | (47.5-160.8) |  | Female | 2 | 4.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 2.9 | nc | (nc-nc) |  | Male | 3 | 3.7 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 4 | 4.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 42 | 39.6 | 106.0 | (76.4-143.3) |
| Female | 2 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 5.5 | 126.9 | (50.8-261.5) |  | Male | 0 | 2.5 | nc | (nc-nc) |
| Female | 2 | 3.6 | nc | (nc-nc) |  | Female | 2 | 1.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 4.0 | 125.4 | (40.4-292.7) |  | Male | 1 | 2.2 | nc | (nc-nc) |
| Female | 2 | 3.2 | nc | (nc-nc) |  | Female | 9 | 6.5 | 138.3 | (63.1-262.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 3.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 10 | 10.3 | 97.2 | (46.5-178.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 17 | 19.8 | 85.8 | (50.0-137.4) |  | Male | 140 | 141.0 | 99.3 | (83.5-117.2) |
| Female | 8 | 22.6 | 35.4 | (15.2-69.8) |  | Female | 141 | 150.6 | 93.6 | (78.8-110.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

261

# Rowe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 1 | 2.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 2 | 2.7 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  | Male | 5 | 9.7 | 51.6 | (16.6-120.4) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 2 | 7.6 | nc | (nc-nc) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

262

# Rowley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 5.7 | 104.9 | (38.3-228.3) |  | Male | 3 | 4.0 | nc | (nc-nc) |
| Female | 1 | 2.0 | nc | (nc-nc) |  | Female | 4 | 3.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 2 | 1.0 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 4 | 3.5 | nc | (nc-nc) |
| Female | 27 | 24.8 | 108.7 | (71.6-158.1) |  | Female | 4 | 2.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 3.1 | nc | (nc-nc) |
| Female | 2 | 0.9 | nc | (nc-nc) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 6.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 6 | 6.3 | 95.9 | (35.0-208.7) |  | Female | 2 | 2.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 1.7 | 296.3 | (95.5-691.4) |  | Male | 4 | 2.1 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 2 | 1.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 25 | 23.6 | 105.8 | (68.5-156.2) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 3.6 | nc | (nc-nc) |  | Male | 0 | 1.4 | nc | (nc-nc) |
| Female | 4 | 1.9 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 2.4 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 7 | 4.8 | 145.3 | (58.2-299.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 2.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 5 | 5.7 | 88.2 | (28.4-205.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 9 | 10.8 | 83.6 | (38.2-158.8) |  | Male | 73 | 83.5 | 87.4 | (68.5-109.9) |
| Female | 4 | 10.5 | nc | (nc-nc) |  | Female | 84 | 80.0 | 105.0 | (83.7-129.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

263

# Royalston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 7 | 5.2 | 133.7 | (53.6-275.4) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 7 | 6.2 | 113.0 | (45.3-232.7) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 1 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 2.8 | nc | (nc-nc) |  | Male | 19 | 21.4 | 88.6 | (53.3-138.4) |
| Female | 3 | 2.1 | nc | (nc-nc) |  | Female | 18 | 16.5 | 109.0 | (64.6-172.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

264